4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

Désirée Mfm van der HeijdeAtul DeodharOliver FitzGeraldRoy M FleischmannDafna GladmanAlice B GottliebBengt HoepkenLars BauerOscar Irvin-SellersMajed KhraishiLuke PetersonAnthony TurkiewiczJürgen WollenhauptPhilip J Mease

Published in: RMD open (2018)

CZP efficacy in treating PsA was maintained over 4 years, in patients both with and without prior anti-TNF exposure, with no new safety signals identified.

Keyphrases

prostate cancer
end stage renal disease
clinical trial
ejection fraction
double blind
newly diagnosed
chronic kidney disease
study protocol
rheumatoid arthritis
radical prostatectomy
prognostic factors
patient reported outcomes
patient reported